Does Highmark Cover Metformin?

Highmark's Formulary Placement for Metformin

Generic metformin hydrochloride sits at Tier 1 (preferred generic) across Highmark's commercial PPO, EPO, and HMO formularies. This placement means the lowest possible cost-sharing for members.

Highmark publishes formulary documents annually for each plan type. The 2025 to 2026 commercial formulary lists metformin immediate-release tablets (500 mg, 850 mg, 1,000 mg) and metformin extended-release tablets (500 mg, 750 mg, 1,000 mg) without step therapy or prior authorization requirements. Metformin is classified by the FDA as a first-line agent for type 2 diabetes, and its generic availability since 2002 keeps acquisition costs below $4 per month at many pharmacies 1.

The American Diabetes Association's 2024 Standards of Care position metformin as first-line pharmacotherapy for type 2 diabetes in adults with an A1c above 6.5%, reinforcing why every major insurer covers it without barriers 2. Highmark follows this guideline closely. Members who need metformin for pre-diabetes prevention (an off-label but evidence-based use supported by the Diabetes Prevention Program trial) can also obtain coverage, though some plans may require a supporting diagnosis code.

The Diabetes Prevention Program Research Group demonstrated that metformin 850 mg twice daily reduced diabetes incidence by 31% over 2.8 years compared with placebo (N=3,234) 3. This trial data underpins Highmark's decision to maintain metformin at the lowest cost tier across plan types.

Copay and Cost-Sharing Breakdown by Plan Type

For most Highmark members, generic metformin costs between $0 and $15 per fill. The exact copay depends on the specific plan metal tier, network, and whether the member has met their deductible.

Highmark's ACA marketplace Silver plans in Pennsylvania typically charge a $10 copay for Tier 1 generics after a $0 pharmacy deductible. Gold plans often reduce this to $5 or waive it entirely. Bronze plans may apply the full pharmacy deductible first, meaning members pay out-of-pocket until reaching $250, $500, after which the $10 copay applies.

Highmark Medicare Advantage plans (Freedom Blue, Community Blue) place generic metformin in the "preferred generic" tier with $0, $3 copays during the initial coverage phase. Once a member enters the coverage gap (the "donut hole"), the Inflation Reduction Act caps insulin and diabetes drug costs, and metformin generics remain at $0 through the catastrophic phase under the 2025 Medicare Part D redesign 4.

For employer-sponsored Highmark plans, copays vary by employer contract. Large-group plans frequently negotiate $0 copays for all preferred generics. Self-insured employers using Highmark's pharmacy benefit management arm may set custom tiers, but metformin almost universally lands at the lowest one given its $0.03-per-tablet wholesale cost.

Brand-Name Metformin: Glucophage, Glumetza, and Riomet

Brand-name formulations carry higher cost-sharing. Glucophage (brand immediate-release) and Glucophage XR sit on Tier 3 in most Highmark formularies, meaning copays of $40, $75 per fill.

Glumetza, an extended-release brand with a different matrix delivery system, is classified as non-preferred brand (Tier 3 or Tier 4) on Highmark plans. Some formularies exclude it entirely, requiring members to use generic metformin ER instead. Riomet, the liquid formulation of metformin used in pediatric patients or adults with swallowing difficulties, typically requires prior authorization and lands on Tier 3.

If a prescriber writes "dispense as written" for a brand product, the member bears the difference between brand and generic cost. Highmark's formulary exception process allows appeals when a member demonstrates medical necessity for a specific brand formulation, such as documented intolerance to all generic manufacturers' inactive ingredients. The exception request requires a letter from the prescribing physician and typically takes 72 hours for standard review or 24 hours for expedited review.

Prior Authorization and Step Therapy Rules

Standard-dose generic metformin does not require prior authorization on any current Highmark formulary. This applies to doses up to 2,550 mg per day (the FDA-approved maximum).

Step therapy is not applied to metformin because it already occupies the first-step position in diabetes treatment algorithms. Highmark does apply step therapy to newer diabetes agents (GLP-1 receptor agonists, SGLT2 inhibitors) by requiring a trial of metformin first. The 2024 ADA Standards of Care note that metformin should be initiated at diagnosis alongside lifestyle intervention unless contraindicated by an eGFR below 30 mL/min/1.73m² 2.

One scenario that may trigger utilization review: doses above 2,550 mg daily or prescriptions written for weight management without a diabetes or pre-diabetes diagnosis code. In these cases, Highmark's pharmacy benefit manager may flag the claim. The prescriber then submits clinical documentation supporting the indication. Off-label metformin for longevity purposes (inspired by the TAME trial design) currently lacks a billable diagnosis code that guarantees automatic adjudication, though ICD-10 code Z79.84 (long-term use of oral hypoglycemic drugs) paired with E11.65 or R73.03 (pre-diabetes) typically resolves the issue.

How to Verify Your Specific Highmark Coverage

Formulary placement can shift between plan years. Three reliable methods exist to confirm your current metformin coverage.

First, log into the Highmark member portal at highmark.com and select "Find a Drug" under the pharmacy benefits tab. Enter "metformin" and the tool displays your plan-specific tier, copay, quantity limits, and any restrictions. Second, call the number on the back of your Highmark ID card and ask the pharmacy representative to run a test claim for metformin 1,000 mg #60 at your preferred pharmacy. This gives you the exact out-of-pocket cost before you fill the prescription. Third, ask your pharmacist to submit the claim at the counter. Metformin is inexpensive enough that even if a coverage issue arises, the cash price (often $4, $10 at major chains through discount programs) remains affordable while you resolve the administrative issue.

Highmark operates across Pennsylvania, West Virginia, Delaware, and parts of New York under various subsidiary names (Highmark Blue Cross Blue Shield, Highmark Blue Shield, Highmark Western New York). Formularies differ slightly between these entities, particularly for Medicare Advantage products. The CMS Medicare Plan Finder tool at medicare.gov allows comparison of Highmark MA-PD plans by drug coverage 5.

Metformin for Longevity: Coverage Considerations

The TAME (Targeting Aging with Metformin) trial, led by Dr. Nir Barzilai at Albert Einstein College of Medicine, is designed to test whether metformin extends healthspan in non-diabetic adults aged 65 to 79. While TAME has not yet reported primary outcomes, its design reflects growing interest in metformin as a geroprotective agent 6.

Dr. Barzilai stated in a 2023 presentation to the American Federation for Aging Research: "Metformin is the first drug to be tested for its ability to delay multiple age-related diseases simultaneously. If TAME succeeds, it would change how the FDA categorizes aging itself." This positions metformin uniquely among drugs with potential longevity applications.

For Highmark members seeking metformin off-label for longevity, coverage hinges on the diagnosis code submitted. A pre-diabetes diagnosis (impaired fasting glucose, A1c 5.7 to 6.4%) paired with metformin automatically adjudicates at Tier 1. Without a qualifying metabolic diagnosis, the claim may reject. However, given metformin's GoodRx cash price of $4, $15 per month, many patients pursuing longevity use simply pay out-of-pocket rather than manage insurance coding complexities.

Observational data from the UK Clinical Practice Research Datalink (N=78,241 matched diabetic patients on metformin vs. 90,463 non-diabetic controls) showed that type 2 diabetics on metformin had 15% lower all-cause mortality than non-diabetic controls, suggesting a potential life-extending effect beyond glucose control 7.

Quantity Limits and Refill Policies

Highmark applies standard quantity limits to metformin that align with FDA-approved dosing. The maximum allowed per 30-day fill is 120 tablets of 500 mg (supporting 2,000 mg daily in divided doses) or 60 tablets of 1,000 mg.

For metformin ER, the typical limit is 60 tablets of 750 mg or 30 tablets of 1,000 mg per 30 days, corresponding to a maximum of 1,500 to 2,000 mg daily. Prescriptions exceeding these quantities require a quantity limit exception, which the prescriber submits with clinical justification.

Mail-order pharmacy through Highmark's preferred mail service (often Express Scripts or a Highmark-owned entity) provides 90-day supplies at reduced cost-sharing, typically two times the 30-day copay. A member paying $10 per 30-day fill would pay $20 for a 90-day mail-order supply. This saves both money and the inconvenience of monthly pharmacy visits.

Early refill policies allow members to refill metformin at 75% through the supply (day 22 to 23 of a 30-day fill). Vacation overrides permit a one-time early refill for travel, available by calling the pharmacy benefit line.

Switching to Highmark: Transition Supply Rules

Members new to Highmark (through open enrollment, job change, or Medicare aging-in) receive transition supply protections. For the first 90 days of a new plan, Highmark must fill any previously covered medication at a 30-day supply, even if the drug sits on a different tier or requires prior authorization on the new formulary.

This protection, mandated by CMS for Medicare plans and adopted voluntarily by Highmark for commercial plans, ensures continuity of metformin therapy during the transition. Given that metformin is Tier 1 on essentially all Highmark formularies, transition issues are rare for this specific drug. They arise more commonly when members switch from brand Glumetza (covered on a prior insurer's formulary) to a Highmark plan that excludes it.

The Endocrine Society's 2022 clinical practice guideline on diabetes management emphasizes uninterrupted metformin therapy once initiated, noting that treatment gaps increase A1c by an average of 0.4% within 3 months 8. Highmark's transition supply policy aligns with this clinical recommendation.

Metformin Contraindications That Affect Coverage

Highmark's drug utilization review system may flag metformin prescriptions when a member's medical claims show eGFR below 30 mL/min/1.73m² (absolute contraindication) or active congestive heart failure with frequent hospitalizations. These are safety flags, not coverage denials.

The FDA updated metformin's renal dosing guidance in 2016, replacing the prior creatinine-based cutoff (1.5 mg/dL for men, 1.4 mg/dL for women) with eGFR thresholds: initiation is appropriate at eGFR ≥45, dose reduction recommended at eGFR 30 to 45, and discontinuation required below 30 1. Highmark's system incorporates these thresholds from lab claims data. If flagged, the pharmacy receives a "DUR reject" that the pharmacist can override after confirming the prescriber reviewed recent renal function.

A Cochrane systematic review of 347 trials found that metformin-associated lactic acidosis occurs at a rate of 6.3 per 100,000 patient-years, which is not significantly different from background rates in diabetic patients on other therapies 9. This evidence supports Highmark's liberal coverage policy without excessive safety barriers.

How Highmark Compares to Other Pennsylvania Insurers

Highmark's metformin coverage mirrors other major Pennsylvania insurers (UPMC Health Plan, Geisinger, Aetna) in tier placement. All place generic metformin at Tier 1 with minimal cost-sharing. The differentiation lies in plan-specific copay amounts and mail-order pricing.

UPMC Health Plan charges $5, $10 for Tier 1 generics on most commercial plans. Geisinger Gold Medicare plans offer $0 copays for preferred generics including metformin. Aetna's Pennsylvania marketplace plans typically apply a $10 copay. Highmark's competitive positioning at $0, $15 for Tier 1 drugs remains standard for the region.

Where Highmark may differ is in its preventive drug list. Certain Highmark ACA-compliant plans include metformin on the preventive medication list at $0 cost-sharing when prescribed for diabetes prevention in patients with pre-diabetes and BMI ≥35. This aligns with the USPSTF Grade B recommendation for metformin in diabetes prevention for high-risk adults 10.

The USPSTF recommendation states: "Clinicians should offer or refer adults aged 35 to 70 years who have overweight or obesity to intensive behavioral counseling interventions to prevent diabetes. Metformin may be considered as an adjunct." This Grade B designation triggers the ACA preventive services mandate, requiring coverage without cost-sharing on compliant plans.